Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
ADP: 571K New Private-Sector Jobs, Better than Expected
by Mark Vickery
571K new private-sector jobs in October surpassed the analyst estimate of 398K by a ton.
Stock Market News for Nov 3, 2021
by Zacks Equity Research
Wall Street maintained its northbound journey on Tuesday with all three major stock indexes closed at record-high levels for three consecutive days.
Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.
5 Blue-Chip Stock to Buy as Dow Crosses a Fresh Milestone
by Nalak Das
We have narrowed down our search to five Dow stocks with strong growth potential for the ensuing quarter. These are: CVX, DOW, MCD, HD and MSFT.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings
by Zacks Equity Research
Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2022 on the third-quarter earnings call.
Fed Set to Start Vital FOMC Meeting
by Zacks Equity Research
Fed Set to Start Vital FOMC Meeting.
Pfizer (PFE) Q3 Earnings Top, COVID Vaccine Drives 2021 View Up
by Zacks Equity Research
Pfizer (PFE) beats third-quarter estimates for earnings and sales, and lifts guidance for 2021.
Fed Meets, Tapering in Our Midst; Pfizer Beats in Q3
by Mark Vickery
The question now is: when will the Fed start tapering, and by how much?
Pfizer (PFE) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 24.07% and 7.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
How Will Pfizer's (PFE) Key Drugs Impact Its Q3 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.
Stock Market News for Nov 1, 2021
by Zacks Equity Research
Wall Street closed higher on Friday despite weak earnings results of a couple of technology behemoths.
Top 6 Momentum Picks for November After a Fabulous October
by Nalak Das
We have narrowed down our search to six large-cap momentum stocks that have strong upside left for the rest of 2021. These are: BX, Ce, CLR, XLNX, BG, GPC.
4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab
by Kinjel Shah
Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.
Why Pfizer (PFE) Might Surprise This Earnings Season
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Glaxo (GSK) Beats on Q3 Earnings, Gives Improved EPS View
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.
Healthcare ETFs in Focus as Q3 Earnings Unfold
by Sweta Killa
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
Will Pfizer (PFE) Keep the Earnings Streak Alive in Q3?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.
Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the third quarter on the back of Revlimid, Eliquis, and Opdivo.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $43.56, moving +0.95% from the previous trading session.
Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.
Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales
by Zacks Equity Research
Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.